🟢 Krystal Biotech Inc is trading 4.8% up today as analysts upgrade targets and Vyjuvek sales drive strong performance

Krystal Biotech Inc is trading at $358.00 (+4.78%) in pre-market following recent positive developments.

• Wall Street analysts, including Jefferies and H.C. Wainwright, have sharply boosted price targets for KRYS, citing renewed confidence in accelerating Vyjuvek sales, progress in pivotal eye-disease trials, and recent UK approval.
• The company reported strong Q1 2026 performance, exceeding earnings and revenue forecasts, and recently received UK MHRA marketing authorization for its gene therapy VYJUVEK.
• This positive sentiment is further supported by an 11-quarter streak of positive earnings per share, driven by Vyjuvek, and expectations of continued expansion into new regions.